Steven Leonard Chapman Sells 160,703 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 160,703 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the sale, the chief executive officer directly owned 144,816 shares of the company’s stock, valued at approximately $28,957,407.36. This trade represents a 52.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $449,067.20.
• On Tuesday, October 21st, Steven Leonard Chapman sold 1,603 shares of Natera stock. The shares were sold at an average price of $187.95, for a total transaction of $301,283.85.
• On Wednesday, October 1st, Steven Leonard Chapman sold 14,083 shares of Natera stock. The shares were sold at an average price of $160.00, for a total transaction of $2,253,280.00.
• On Tuesday, September 30th, Steven Leonard Chapman sold 9,109 shares of Natera stock. The shares were sold at an average price of $162.05, for a total transaction of $1,476,113.45.
• On Tuesday, September 2nd, Steven Leonard Chapman sold 5,079 shares of Natera stock. The shares were sold at an average price of $166.53, for a total transaction of $845,805.87.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $196.45 on Wednesday. The company has a market cap of $26.96 billion, a price-to-earnings ratio of -102.85 and a beta of 1.75. The firm has a 50 day simple moving average of $175.77 and a 200 day simple moving average of $162.77. Natera, Inc. has a one year low of $122.08 and a one year high of $203.23.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter last year, the company posted ($0.30) earnings per share. The company’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NTRA. GAMMA Investing LLC boosted its stake in Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock worth $120,000 after acquiring an additional 207 shares in the last quarter. Amalgamated Bank lifted its stake in shares of Natera by 9.8% in the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock valued at $1,173,000 after buying an additional 740 shares in the last quarter. Private Trust Co. NA lifted its stake in shares of Natera by 780.1% in the first quarter. Private Trust Co. NA now owns 1,461 shares of the medical research company’s stock valued at $207,000 after buying an additional 1,295 shares in the last quarter. Calamos Advisors LLC lifted its stake in shares of Natera by 29.0% in the first quarter. Calamos Advisors LLC now owns 29,637 shares of the medical research company’s stock valued at $4,191,000 after buying an additional 6,667 shares in the last quarter. Finally, Ninety One UK Ltd bought a new position in shares of Natera in the first quarter valued at $31,959,000. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price target for the company in a research report on Monday, July 28th. Barclays reiterated an “overweight” rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Piper Sandler reiterated an “overweight” rating and set a $220.00 price objective (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Finally, BNP Paribas upgraded shares of Natera to a “hold” rating and set a $172.00 price objective for the company in a research report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $194.89.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.